Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib or Buparlisib with Tamoxifen and Goserelin in Premenopausal Breast Cancer
NCT02058381Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of alpelisib and buparlisib in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase II Dose at 12 months. Started May 2014; status: completed.
02
Drugs
alpelisibbuparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02058381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058381.